← Study Library
Meta-analysis · 2020 · n=4,674
Strongcounts toward this tierInterventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis
Imamura M, Scott NW, Wallace SA, Ogah JA, Ford AA, Dubos YA, Brazzelli M · The Cochrane Database of Systematic Reviews
Strongcounts toward this tier
The independent counterweight to the sponsor-supported pooling: PPS showed no evidence of improved cure or improvement (odds ratio 0.14, 95% credible interval 0.40 to 3.35) and no reduction in pain (mean difference 0.42, 95% CrI −1.04 to 1.91), frequency or nocturia, all at low or very low certainty. Antidepressants and neuromuscular blockade were the two categories that separated from control.
- Population
- 81 randomized trials, 4,674 people with bladder pain syndrome, 65 active treatments grouped into 31 categories
- Intervention
- All interventions for bladder pain syndrome, including oral PPS
- Comparator
- Control, within a Bayesian network
- Limitations
- Certainty was low or very low throughout because the underlying trials are small and heterogeneous, so this is an absence of demonstrated benefit rather than a demonstration of absent benefit; UK NIHR-funded, no author conflicts declared.
Cited by
1 entry references this study
- Pentosan polysulfate (PPS)PROM.
Peptides → Clinically studied